# Compounded Semaglutide vs Ozempic and Wegovy: What Is Actually Different

By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-08-14 | Updated: 2026-11-06

Canonical page: https://glpwatchdog.org/research/compounded-semaglutide-vs-brand-semaglutide

> The molecule inside compounded semaglutide can be the one in Ozempic and Wegovy. What differs is everything around it: how it is formulated, at what concentration, on what dose ladder, and with what adverse-event record behind it.

## Key points

- Semaglutide sodium and semaglutide acetate are not the approved drugs' active ingredient, and FDA is not aware of a lawful basis for compounding with them.
- Ozempic and Wegovy are the same molecule; what differs is the approved indication and the ceiling: 2 mg once weekly against a usual maintenance of 2.4 mg.
- FDA does not review a compounded drug for safety, effectiveness or quality before it reaches a patient, so there is no reviewed dose ladder behind the vial.
- 990 adverse-event reports on compounded semaglutide as of May 31, 2026, and a state-licensed pharmacy that is not an outsourcing facility is not required to submit them at all.

The active molecule can be identical. Almost nothing else is. An approved semaglutide product carries a formulation, a manufacturing process and a printed label that FDA reviewed before anyone injected it; a compounded vial carries none of those reviews, and FDA says so plainly.[2]

## Start with what is identical

Semaglutide is a specific molecule. Both approved labels describe it in the same terms: the same molecular formula, the same molecular weight of 4113.58 g/mol, the same peptide backbone produced by yeast fermentation.[4][5] A compounded preparation containing semaglutide base contains that molecule. Anyone telling you the compounded version is a different drug in that narrow sense is wrong.

Hold on to the word *base*, because it is where the sentence stops being reliable.

## A salt of semaglutide is a different ingredient

FDA has said some semaglutide sold by compounders is a salt of the molecule rather than the base. Semaglutide sodium and semaglutide acetate are, in the agency's assessment, **different active ingredients** from the one in the approved products. FDA adds that it holds no information on whether those salts behave the same way chemically or pharmacologically, and that it is not aware of a lawful basis for using them in compounding at all.[1]

This is the most consequential difference here, and a marketing site will not show it. A page that says “semaglutide” does not tell you which form is in the vial; the label and the pharmacy can. When a seller will not name the pharmacy that compounded its product, our [pharmacy register](https://glpwatchdog.org/pharmacies) records that as a finding.

## Ozempic and Wegovy are one molecule with two labels

Most readers comparing compounded semaglutide to Ozempic have a second misconception underneath the first: that Ozempic and Wegovy are different drugs. They are the same molecule. What differs is what each was approved to treat and how high its dosing is allowed to go.

*The two approved semaglutide injections, from their current prescribing information*

|   | Ozempic | Wegovy injection |
| --- | --- | --- |
| Approved for | Blood-sugar control in type 2 diabetes, and two outcome indications within that same population: heart-event risk where cardiovascular disease is already present, and kidney decline in chronic kidney disease[4] | Losing excess weight and holding the loss — for obesity from age 12 upward, and for adults carrying extra weight who also have a condition related to it; heart-event risk where cardiovascular disease is already established and weight is a factor; and noncirrhotic MASH at fibrosis stages F2 to F3[5] |
| Starting dose | 0.25 mg once weekly for 4 weeks[4] | 0.25 mg once weekly for 4 weeks[5] |
| Usual ceiling | Maintenance of 0.5 mg, 1 mg or 2 mg weekly; the maximum recommended dosage is 2 mg once weekly[4] | Usual maintenance 2.4 mg once weekly, with a higher-dose presentation also approved[5] |
| How a dose is delivered | Single-patient-use pens that deliver fixed increments, plus single-dose prefilled syringes[4] | Single-dose pens and syringes, plus a multi-dose pen that delivers four fixed doses[5] |

So “compounded semaglutide vs Ozempic” and “compounded semaglutide vs Wegovy” share one answer about chemistry. They differ only in which reviewed label you are stepping outside of.

## A compounded vial has no approved label, so it has no reviewed dose ladder

[The escalation schedule](https://glpwatchdog.org/learn/glp-1-medications/semaglutide-dosing-schedule) on an approved label is part of what FDA reviewed. Both semaglutide labels open at 0.25 mg weekly for four weeks and step up on a fixed cadence, and the Ozempic label states its own maximum in a sentence.[4][5] A compounded product has no such document behind it, because FDA does not evaluate a compounded drug's safety, effectiveness or quality before it reaches a patient.[2]

The consequence shows up in FDA's adverse-event reports. The agency reports adverse events from patients prescribed compounded semaglutide or tirzepatide at doses beyond what the approved labeling describes: more product in a single dose, doses taken more often, or the amount increased faster than the approved titration.[1] None of those three is a manufacturing failure. Each is a decision that an approved label would have constrained and a compounded preparation does not.

> **Nothing on this page is a dose instruction.** If your dose, your schedule or your next step up is the question, it belongs to the prescriber managing your treatment and the pharmacy that filled it.

## A concentration is not a dose

Approved presentations hand you a dose. The Ozempic cartons say the pen delivers doses in fixed increments and nothing else; the multi-dose Wegovy pen holds 9.6 mg in 3 mL and delivers four 2.4 mg doses.[4][5] Even where a concentration appears, the device meters the amount for you.

A compounded multi-dose vial is sold as a concentration, in milligrams per milliliter, and the dose is arithmetic that someone has to do correctly with a syringe. [Three cases that reached a regional poison center](https://glpwatchdog.org/research/lists/top-compounded-glp1-bioequivalence-quality-studies) show what that costs when it goes wrong: two patients self-administered 10-fold overdoses, one measured doses in milliliters and units instead of milligrams, and one had been handed a vial and syringes with no counseling on how to use them. The authors' conclusion was that these vials lack the safety features built into prefilled manufactured pens.[6] Three cases do not make a rate, but they match the mechanism FDA describes when it reports [dosing-error adverse events](https://glpwatchdog.org/research/qna/top-compounded-vs-brand-glp1-questions-reddit-answered), some requiring hospitalization, from patients measuring and self-administering incorrect amounts.[1] What too large a dose does, and what to do about one, is in [GLP-1 overdose: what happens](https://glpwatchdog.org/research/glp1-overdose-what-happens).

## Extra ingredients make it a different preparation

Compounded vials sometimes list a second active ingredient beside the semaglutide, cyanocobalamin among them, and enough sellers price a B12 version that we list them on [a board of their own](https://glpwatchdog.org/best/compounded-semaglutide/with-b12). No approved semaglutide injection, Ozempic or Wegovy, contains a vitamin of any kind.[4][5] What the Ozempic label lists alongside the drug is unglamorous and short: disodium phosphate dihydrate, propylene glycol, phenol and water for injections in the pen presentation, and a different set again in the single-dose syringe (disodium phosphate dihydrate, sodium chloride and water for injection).[4]

Two presentations of the same approved drug carry different excipients, each reviewed for the presentation it belongs to. It is a small illustration of what approval covers: not the molecule in the abstract, but this formulation, in this container, at this strength. The B12 question is covered in [why compounded semaglutide is mixed with B12](https://glpwatchdog.org/research/semaglutide-compounded-with-b12).

## The safety record you can look up is not the same size

FDA has received 990 adverse-event reports involving compounded semaglutide and more than 730 involving [compounded tirzepatide](https://glpwatchdog.org/research/compounded-tirzepatide-vs-zepbound), counted as of May 31, 2026. The agency notes that many of them look consistent with events already known for the approved versions. It also notes the reason those numbers understate the picture: federal law does not require a state-licensed pharmacy that is not an outsourcing facility to submit adverse events to FDA at all, so reports from compounded products are likely undercounted.[1]

Outsourcing facilities sit under different obligations. Registered under section 503B, they are subject to current good manufacturing practice requirements, are inspected by FDA on a risk-based schedule, and do have to report adverse events.[2] Two vials of compounded semaglutide can therefore come with meaningfully different amounts of public evidence behind them, and neither carries as much as an approved product.

> **This is a claim about process, not outcome.** No head-to-head evidence shows that a compounded vial is more harmful or works less well. What is documented is the gap in review, in labeling and in reporting, and that gap is worth knowing before you choose.

## Where the legal position now stands

The comparison used to have a third element: availability. Compounded semaglutide was widely lawful to sell because the drug was in shortage. That determination flipped on February 21, 2025. FDA then let its enforcement discretion run to April 22, 2025 for state-licensed pharmacies and to May 22, 2025 for outsourcing facilities.[3] In its April 1, 2026 update the agency recorded that neither molecule sits on the 503B bulks list, and that neither is in shortage.[3] A month later FDA formally proposed not to add semaglutide, tirzepatide or liraglutide to that list, on the view that 503B facilities have no clinical reason to make them from raw substance.[7] Comments closed on July 30, 2026. As of October 17, 2026, no final determination has been published.[8]

Compounding for an individual patient with a documented need did not end, and our [breakdown of which GLP-1s can still be compounded](https://glpwatchdog.org/research/which-glp1-can-be-compounded) sets out what that requires. If a program you are already on has stopped, [what to do next](https://glpwatchdog.org/research/compounded-glp1-going-away-what-to-do) covers the routes that remain.

## Five questions that separate the two products

1. **Is this semaglutide base, or a salt?** Ask for the form by name. FDA says it is aware of no legal basis for compounding with semaglutide sodium or semaglutide acetate.[1]
2. **Which pharmacy compounded it, and under 503A or 503B?** The answer changes the manufacturing standard, the inspection schedule and whether adverse events reach FDA at all.[2]
3. **What is the concentration, and how many units is my dose?** Ask in the units printed on the syringe you were sent, not in milligrams alone.[6]
4. **What else is in the vial?** A second active ingredient makes it a different preparation from anything approved.[4]
5. **What happens to the price when the dose goes up?** Where a program prices by strength, the figure climbs with the ladder, and the ladder climbs by design. We track what sellers charge on the [live price tracker](https://glpwatchdog.org/price-tracker) and rank the compounded market on [/best/compounded-semaglutide](https://glpwatchdog.org/best/compounded-semaglutide).

Sellers of compounded semaglutide answer that last question differently. [Dollar Dad Club](https://glpwatchdog.org/reviews/dollar-dad-club), [JustAnswer Weight Loss](https://glpwatchdog.org/reviews/justanswer-weight-loss) and [NiceRx](https://glpwatchdog.org/reviews/nicerx) charge one price at every dose. [LovelyMeds](https://glpwatchdog.org/reviews/lovelymeds) and [Rivas Medical Weight Loss](https://glpwatchdog.org/reviews/rivas-medical) do the same, and [Fresh Day Meds](https://glpwatchdog.org/reviews/fresh-day) labels each of its plans “all doses.” [Yes Clinic](https://glpwatchdog.org/reviews/yes-clinic) also holds one price across doses but sells semaglutide only in plans of three months or longer, paid up front.

Others price by strength. At [Nova](https://glpwatchdog.org/reviews/nova-trynova) and [Vitakey](https://glpwatchdog.org/reviews/vitakey) the figure moves with the dose, and Vitakey sells its [microdose plan](https://glpwatchdog.org/research/glp1-microdosing-price-check) separately from its full weight-loss dose. On the pharmacy question, [TotalRx](https://glpwatchdog.org/reviews/totalrx) names its pharmacy partners, though the plan length and the real charge appear only after its medical intake.

Some publish nothing to compare. [Male Excel](https://glpwatchdog.org/reviews/male-excel), a men’s hormone clinic, bills GLP-1 medication on top of a $99 monthly membership, at member prices its site does not show. [LiveNow Longevity](https://glpwatchdog.org/reviews/livenow-longevity), a Las Vegas physician practice, bills medication at the pharmacy’s cost with no markup and quotes its management fee only after an $88 evaluation.

One answer is disqualifying on its own. FDA's list of telehealth warning signs opens with a company that claims its compounded drug is the same as an FDA-approved drug.[1] A seller that makes that claim fails FDA's first check.

Versions of that claim are still easy to find. [FWD Care](https://glpwatchdog.org/reviews/fwd-care) was sent an FDA warning letter in September 2025 for claims such as “Same active ingredient as Ozempic and Wegovy.” [YesYouCan! Medical](https://glpwatchdog.org/reviews/yesyoucan-medical) calls its compounded GLP-1 “the same GLP-1 medicine the branded names use.” The FAQ at [Phoenix Weight Loss and Wellness](https://glpwatchdog.org/reviews/phoenix-weight-loss) calls compounded semaglutide “safe,” with “the same” safety profile as the brand versions. [Direct Meds](https://glpwatchdog.org/reviews/direct-meds) got one the same month, citing claims such as “Same active ingredient as Ozempic and Wegovy” and “Clinically proven ingredients.”

## Frequently asked questions

### Is compounded semaglutide the same as Ozempic?

Not as a product. It may contain the same molecule, but the specific preparation, its concentration, its container and its labeling were never reviewed by FDA, which does not evaluate compounded drugs for safety, effectiveness or quality before they reach patients. FDA also treats a company claiming that a compounded drug is the same as an FDA-approved drug as a consumer warning sign.

### What is the difference between Ozempic and Wegovy?

The molecule is the same. The approved uses and the dosing ceilings are not. Ozempic's label covers blood-sugar control in type 2 diabetes plus heart and kidney outcomes within that population, and it names 2 mg once weekly as the maximum recommended dosage. Wegovy injection covers weight loss and its maintenance from age 12 upward, heart-event risk where weight and existing cardiovascular disease occur together, and noncirrhotic MASH at moderate to advanced fibrosis, with a usual maintenance dosage of 2.4 mg once weekly.

### Is compounded semaglutide weaker than the brand?

There is no head-to-head evidence either way, and anyone telling you otherwise is going beyond the record. The verifiable difference is that an approved product's strength was reviewed and is delivered by a device that meters it, while a compounded vial is supplied as a concentration and the dose is measured by the person injecting it.

### Why do compounded vials often contain B12?

Several reasons get offered to buyers and only one of them has a federal document behind it. FDA has used semaglutide combined with vitamin B12 as its own worked example of a combination it may still treat as essentially a copy of an approved product. Our article on semaglutide compounded with B12 covers that worked example in full.

### Is compounded semaglutide still legal to buy?

Compounding for an identified patient whose documented need an approved product cannot meet remains lawful. What ended was the shortage-based permission that supported selling it at scale. The shortage determination flipped on February 21, 2025, enforcement discretion ran to April 22, 2025 for state-licensed pharmacies and to May 22, 2025 for outsourcing facilities, and by the agency's April 1, 2026 update neither molecule sat on the 503B bulks list or in shortage. FDA has since proposed keeping semaglutide off that list; as of October 17, 2026 the proposal had not been finalized.

## References

1. U.S. Food and Drug Administration FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. FDA Drug Alerts and Statements. 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
2. U.S. Food and Drug Administration Human Drug Compounding Laws. FDA Human Drug Compounding. 2024. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
3. U.S. Food and Drug Administration FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. FDA Drug Alerts and Statements. 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
4. Novo Nordisk Pharmaceutical Industries, LP OZEMPIC (semaglutide) injection, for subcutaneous use — prescribing information. DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
5. Novo Nordisk Pharmaceutical Industries, LP WEGOVY (semaglutide) injection and tablets — prescribing information. DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
6. Lambson JE, Flegal SC, Johnson AR. Administration errors of compounded semaglutide reported to a poison control center-Case series. J Am Pharm Assoc (2003) 2023;63(5):1643-1645. 2023. PMID: 37392810. https://pubmed.ncbi.nlm.nih.gov/37392810/
7. U.S. Food and Drug Administration List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act. Federal Register (2026-08552), 91 FR 23431. 2026. https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
8. U.S. Food and Drug Administration List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period. Federal Register (2026-12937). 2026. https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal

---

Cite as: GLP Watchdog, Ruth Calder, "Compounded Semaglutide vs Ozempic and Wegovy: What Is Actually Different", published 2026-08-14, updated 2026-11-06. https://glpwatchdog.org/research/compounded-semaglutide-vs-brand-semaglutide

Canonical HTML page: https://glpwatchdog.org/research/compounded-semaglutide-vs-brand-semaglutide

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
